Provided by Tiger Fintech (Singapore) Pte. Ltd.

CNS Pharmaceuticals, Inc.

0.8000
+0.04205.54%
Post-market: 0.83000.0300+3.75%19:25 EDT
Volume:132.36K
Turnover:102.89K
Market Cap:4.37M
PE:-0.02
High:0.8400
Open:0.7693
Low:0.7340
Close:0.7580
Loading ...

CNS Pharmaceuticals Announces Promising Results for TPI 287 in Glioblastoma Treatment at 2025 Brain Tumor Biotech Summit

Reuters
·
05 Jun

CNS Pharmaceuticals Q4 EPS $(1.58) Beats $(6.00) Estimate

Benzinga
·
16 May

CNS Pharmaceuticals Reports Q1 2025 Financials: Net Loss Increases to $4.3 Million, R&D Expenses Rise

Reuters
·
16 May

CNS Pharmaceuticals Q1 Net Income USD -4.3 Million

THOMSON REUTERS
·
16 May

CNS Pharmaceuticals Inc. Raises $5 Million Through Public Offering of Common Stock and Warrants

Reuters
·
15 May

Sector Update: Health Care Stocks Decline Tuesday Afternoon

MT Newswires Live
·
14 May

Wall Street Set to Open Mixed Tuesday as Inflation Reading Lower Than Expected

MT Newswires Live
·
13 May

Sector Update: Health Care Stocks Mixed Premarket Tuesday

MT Newswires Live
·
13 May

CNS Pharmaceuticals Acquires Orphan Drug Designation for TPI 287 in Glioblastoma

MT Newswires Live
·
13 May

CNS Pharmaceuticals reports FY24 EPS ($38.87) vs. ($12,509.11) last year

TipRanks
·
02 Apr

CNS Pharmaceuticals Reports Full Year 2024 Financial Results

ACCESS Newswire
·
01 Apr

CNS Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
01 Apr

CNS Pharmaceuticals Inc expected to post a loss of $9.66 a share - Earnings Preview

Reuters
·
28 Mar

CNS Pharmaceuticals announces primary analysis of berubicin in GBM

TIPRANKS
·
26 Mar

CNS Pharmaceuticals Cut to Hold From Buy by Maxim Group

Dow Jones
·
26 Mar

CNS Pharma Shares Sink After Berubicin Trial for Brain Cancer Misses Survival Endpoint

Dow Jones
·
25 Mar

CNS Pharmaceuticals - Berubicin Showed Clinically Relevant Outcomes Comparable to Lomustine Across Multiple Endpoints

THOMSON REUTERS
·
25 Mar

CNS Pharmaceuticals Inc: Berubicin Did Not Show a Statistically Significant Difference in Overall Survival, the Primary Endpoint

THOMSON REUTERS
·
25 Mar

CNS Pharmaceuticals Inc -Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme

THOMSON REUTERS
·
25 Mar

CNS Pharmaceuticals-Continues Development of Novel Taxane, TPI 287, With Published Clinical Efficacy Data in Glioblastoma Multiforme

THOMSON REUTERS
·
25 Mar